Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global
commercial-stage biopharmaceutical company focused on transforming
the lives of patients and their families living with rare
neuroendocrine diseases, today reported financial results and
provided a business update for the fourth quarter and full year
ended December 31, 2023.
“2023 was a strong year for us as we delivered IMCIVREE®
(setmelanotide) and provided support for patients and families
living with hyperphagia and severe obesity caused by rare
melanocortin-4 receptor (MC4R) pathway diseases in 14 countries,
including the United States,” said David Meeker, M.D., Chair,
President and Chief Executive Officer of Rhythm. “We began this
year by meaningfully strengthening our pipeline with RM-718 ready
to enter the clinic and with the acquisition of the global rights
to LB54640.”
He continued, “Importantly, we remain focused on developing
setmelanotide to treat patients with hypothalamic obesity, for whom
there are no approved therapies. We are pleased to have completed
enrollment in our global Phase 3 trial in hypothalamic obesity and
to have achieved alignment with Japanese authorities on an
efficient path to develop setmelanotide for patients with
hypothalamic obesity.”
Fourth Quarter and Recent Business
Highlights
Corporate and Commercial Updates
- Today, Rhythm announced that more than 100 new prescriptions
for IMCIVREE for Bardet-Biedl syndrome (BBS) were written by U.S.
prescribers and that the Company has received payor approval for
reimbursement for 70 prescriptions during the fourth quarter of
2023.
- On February 7, 2024, the Company announced the Italian Medicine
Agency (AIFA) approved reimbursement for IMCIVREE) for the
treatment of obesity and control of hunger associated with
BBS.
- On January 4, 2024, Rhythm announced it entered into a global
licensing agreement with LG Chem, Ltd. ("LG Chem") for LB54640, an
investigational oral small molecule MC4R agonist in Phase 2
clinical trials.
- On January 4, 2024, the Company also announced that federal
healthcare authorities in Spain approved reimbursement for IMCIVREE
for the treatment of obesity and control of hunger associated with
BBS or biallelic POMC, PCSK1 or LEPR deficiency.
Clinical, Research and Regulatory Updates
- Today, Rhythm also announced that it completed enrollment in
the pivotal, 120-patient cohort in its global Phase 3 trial of
setmelanotide in hypothalamic obesity with patients, aged 4 years
or older with hypothalamic obesity randomized 2:1 to setmelanotide
therapy or placebo for a total of 60 weeks, including up to eight
weeks for dose titration. As agreed to with both the United States
Food and Drug Administration (FDA) and the European Medicines
Agency (EMA), Rhythm’s regulatory submissions would be based on
data from this cohort. The Company remains on track to obtain
top-line study results in the first half of 2025.
- Rhythm today also announced its clinical development plan of
setmelanotide for hypothalamic obesity in Japan. The Company will
add a supplemental Japanese patient cohort – designed to enable
registration there - to its Phase 3 trial following an agreement
with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA),
with first patients expected to be dosed during the third quarter
of 2024. Rhythm estimates that hypothalamic obesity has a
prevalence of 5,000 to 8000 patients in Japan.
- On January 4, 2024, Rhythm announced it submitted a Type II
variation application to the EMA seeking regulatory approval and
authorization for setmelanotide to treat obesity and control hunger
in pediatric patients between 2 and younger than 6 years old with
BBS or POMC, PCSK1 or LEPR deficiency in the European Union.
- On January 4, 2024, Rhythm also announced that the FDA accepted
the Company’s Investigational New Drug (IND) application for RM-718
for administration as a weekly therapy treatment. RM-718 is
designed to be more targeted and potent than setmelanotide with the
potential to not cause hyperpigmentation.
- On December 6, 2023, Rhythm announced new data from its
52-week, Phase 3 pediatrics trial in patients between 2 and younger
than 6 years old (N=12) that showed setmelanotide achieved the
primary endpoint with a 3.04 mean reduction in BMI-Z score (a
measure of body mass index deviations from what is considered
normal) and 18.4 percent mean reduction in BMI.
- On December 6, 2023, the Company also announced data from the
open-label part of its exploratory Phase 2 DAYBREAK trial that
demonstrated potential efficacy in patients in multiple
genetically-defined cohorts. A total of 49 patients who completed
Stage 1 with a response to setmelanotide were randomized into Stage
2 of the trial, a 24-week, double-blind, placebo-controlled
withdrawal study. These patients were stratified into genetically
defined cohorts and randomized 2:1 to receive setmelanotide or
placebo.
Corporate and Anticipated Upcoming
Milestones
Rhythm expects to achieve the following near-term
milestones:
- Complete submission of a supplementary New Drug Application
(sNDA) to the FDA seeking a label expansion to treat pediatric
patients between 2 and younger than 6 years old in approved
indications in the first half of 2024;
- Initiate Phase 1 trial of RM-718 in the first half of
2024;
- Announce DAYBREAK Stage 2 data in the second half of 2024;
- Complete enrollment in two or more substudies in the Phase 3
EMANATE trial evaluating setmelanotide in genetically caused MC4R
pathway diseases in the second half of 2024; and
- Announce top-line data in the Phase 3 trial evaluating
setmelanotide in hypothalamic obesity in the first half of
2025.
Fourth Quarter and Full Year
2023 Financial Results:
- Cash Position: As of December 31,
2023, cash, cash equivalents and short-term investments were
approximately $275.8 million, as compared to $333.3
million as of December 31, 2022.
- Revenue: Net product revenues relating to
sales of IMCIVREE were $24.2 million in the fourth quarter of 2023
and $77.4 million for the year ended December 31, 2023, as compared
to $8.8 million for the fourth quarter of 2022 and $16.9
million for the year ended December 31, 2022. For the
years ended December 31, 2023 and 2022, 81% and 85%, respectively,
of the Company’s product revenue was generated in the United
States. For the fourth quarter ended December 31, 2023, 76% of net
product revenue was generated in the United States. Fourth quarter
product revenue was affected by a single state Medicaid program
change to documentation requirements for reimbursement that
resulted in some patients transitioning to the Company’s free-drug
bridging program.
- License Revenue: The Company did not recognize
license revenue in 2023, as compared to $6.8 million in 2022
entirely related to the RareStone license agreement. Rhythm entered
into a license agreement with RareStone in December 2021 and
completed activities required to transfer the license to RareStone
during the second quarter of 2022, which resulted in the
recognition of the license revenue.
- R&D Expenses: R&D expenses
were $29.9 million in the fourth quarter of 2023 and
$135.0 million for the year ended December 31, 2023, as compared to
$23.5 million in the fourth quarter of 2022 and $108.6
million for the year ended December 31, 2022. The
year-over-year increase was primarily due to increased costs
associated with salaries, benefits and stock-based compensation
related to the hiring of additional full-time employees, increases
in clinical trial costs, the purchase of research and development
assets from Xinvento, BV, as well as increased pre-clinical and
gene sequencing costs.
- S,G&A Expenses: S,G&A expenses
were $32.4 million in the fourth quarter of 2023
and $117.5 million for the year ended December 31,
2023, compared to $26.3 million in the fourth quarter of 2022
and $92.0 million for the year ended December 31,
2022. The year-over-year increase was primarily due to increased
compensation and benefits related costs associated with additional
headcount to support our expanding business operations and
commercial operations, as well as increases in professional
services and consulting costs. These increases were partially
offset by decreased costs associated with the IMCIVREE launch for
BBS in 2022 and a decrease in value-added tax expense.
- Other (expense) income, net: Other (expense)
income, net increased by $2.2 million to $0.2 million in 2023, an
increase of 112%, primarily due to higher interest income and
changes in fair value of the embedded derivative liability
associated with deferred royalty obligation, partially offset by an
increase in non-cash interest expense related to amortization of
debt discount and deferred financing fees associated with the
deferred royalty obligation.
- Net Loss: Net loss was $41.6
million for the fourth quarter of 2023 and $184.7
million for the year ended December 31, 2023, or a net
loss per basic and diluted share of ($0.70) and ($3.20),
respectively, as compared to $42.5 million for the fourth
quarter of 2022 and $181.1 million for the year
ended December 31, 2022, or a net loss per basic and diluted
share of ($0.75) and ($3.47), respectively.
Financial Guidance:
For the year ended December 2023, the Company had GAAP total
operating expenses of $261.8 million. The Company today reported
non-GAAP Operating Expenses for the year ended December 31, 2023 of
$219.9 million, which is derived from GAAP total costs and expenses
of $261.8 million less $9.3 million in cost of sales and less $32.6
million in stock-based compensation.
For the year ending December 31, 2024,
Rhythm anticipates approximately $250 million to $270 million in
Non-GAAP Operating Expenses. Non-GAAP Operating Expenses are
derived from:
- GAAP total operating expenses, inclusive of:
- SG&A expenses of $105 million to $110 million; and
- R&D expenses of $145 million to $160 million,
- inclusive of $10 million to $15 million of LB54640 development
costs; but which excludes:
- Stock-based compensation, and
- $100 million in fixed consideration related to in-licensing of
global rights to LB54640, which will be recognized in the first
quarter of 2024.
Non-GAAP Operating Expenses is defined
as GAAP operating expenses excluding stock-based compensation and
fixed consideration related to in-licensing (see below under
"Non-GAAP Financial Measures" for more details).
Based on its current operating plans,
Rhythm expects that its existing cash, cash equivalents and
short-term investments as of December 31, 2023, will be sufficient
to fund its operating expenses and capital expenditure requirements
into the second half of 2025.
Conference Call
InformationRhythm Pharmaceuticals will host a live
conference call and webcast at 8:00 a.m. ET today to review its
fourth quarter and year end 2023 financial results and recent
business activities. Participants may register for the conference
call here. It is recommended that participants join the call ten
minutes prior to the scheduled start.
A live webcast of the call will also be available under "Events
and Presentations" in the Investor Relations section of the Rhythm
Pharmaceuticals website at https://ir.rhythmtx.com/. The archived
webcast will be available on Rhythm Pharmaceuticals’ website
approximately two hours after the conference call and will be
available for 30 days following the call.
About Rhythm PharmaceuticalsRhythm is a
commercial-stage biopharmaceutical company committed to
transforming the lives of patients and their families living with
rare neuroendocrine diseases. Rhythm’s lead asset, IMCIVREE®
(setmelanotide), an MC4R agonist designed to treat hyperphagia and
severe obesity, is approved by the U.S. Food and Drug
Administration (FDA) for chronic weight management in adult and
pediatric patients 6 years of age and older with monogenic or
syndromic obesity due to pro-opiomelanocortin (POMC), proprotein
convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor
(LEPR) deficiency confirmed by genetic testing, or patients with a
clinical diagnosis of Bardet-Biedl syndrome (BBS). Both the
European Commission (EC) and the UK’s Medicines & Healthcare
Products Regulatory Agency (MHRA) have authorized setmelanotide for
the treatment of obesity and the control of hunger associated with
genetically confirmed BBS or genetically confirmed loss-of-function
biallelic POMC, including PCSK1, deficiency or biallelic LEPR
deficiency in adults and children 6 years of age and above.
Additionally, Rhythm is advancing a broad clinical development
program for setmelanotide in other rare diseases, as well as RM-718
and a preclinical suite of small molecules for the treatment of
congenital hyperinsulinism. Rhythm’s headquarters is in Boston,
MA.
Setmelanotide IndicationIn the United
States, setmelanotide is indicated for chronic weight management in
adult and pediatric patients 6 years of age and older with
monogenic or syndromic obesity due to POMC, PCSK1 or LEPR
deficiency as determined by an FDA-approved test demonstrating
variants in POMC, PCSK1 or LEPR genes that are interpreted as
pathogenic, likely pathogenic, or of uncertain significance (VUS)
or BBS.
In the European Union, setmelanotide is indicated for the
treatment of obesity and the control of hunger associated with
genetically confirmed Bardet-Biedl syndrome (BBS) or genetically
confirmed loss-of-function biallelic proopiomelanocortin (POMC),
including PCSK1, deficiency or biallelic leptin receptor (LEPR)
deficiency in adults and children 6 years of age and above.
Limitations of UseIn the United
States and Europe, Setmelanotide should be prescribed and
supervised by a physician with expertise in obesity with underlying
genetic etiology.
Setmelanotide is not indicated for the treatment of patients
with the following conditions as setmelanotide would not be
expected to be effective:
- Obesity due to suspected POMC, PCSK1 or LEPR deficiency
with POMC, PCSK1 or LEPR variants
classified as benign or likely benign
- Other types of obesity not related to POMC, PCSK1 or LEPR
deficiency, or BBS, including obesity associated with other genetic
syndromes and general (polygenic) obesity.
WARNINGS AND PRECAUTIONS
Skin Monitoring: Setmelanotide may lead to
generalized increased skin pigmentation and darkening of
pre-existing naevi because of its pharmacologic effect. Full body
skin examinations should be conducted annually to monitor
pre-existing and new skin pigmentary lesions before and during
treatment with setmelanotide.
Heart rate and blood pressure
monitoring: Heart rate and blood pressure should be
monitored as part of standard clinical practice at each medical
visit (at least every 6 months) for patients treated with
setmelanotide.
Prolonged penile erection: Spontaneous
penile erections have been reported in clinical trials with
setmelanotide. Patients who have a penile erection lasting longer
than 4 hours should be instructed to seek emergency medical
attention for potential treatment of priapism.
Depression: In clinical trials, depression
has been reported in patients treated with setmelanotide. Patients
with depression should be monitored at each medical visit during
treatment with setmelanotide. Consideration should be given to
discontinuing setmelanotide if patients experience suicidal
thoughts or behaviors.
Pediatric Population: The prescribing
physician should periodically assess response to setmelanotide
therapy. In growing children, the impact of weight loss on growth
and maturation should be evaluated. The prescribing physician
should monitor growth (height and weight) using age- and
sex-appropriate growth curves.
Excipients: This medicinal product
contains 10 mg benzyl alcohol in each ml. Benzyl alcohol may cause
allergic reactions. Patients who are pregnant or breastfeeding
should be advised of the potential risk from the excipient benzyl
alcohol, which might accumulate over time and cause metabolic
acidosis. This medicinal product should be used with caution in
patients with hepatic or renal impairment, because of the potential
risk from the excipient benzyl alcohol which might accumulate over
time and cause metabolic acidosis.
Sodium: This medicinal product contains
less than 1 mmol sodium (23 mg) per dose, that is to say
essentially “sodium-free.”
ADVERSE REACTIONSThe most frequent adverse
reactions are hyperpigmentation (51%), injection site reaction
(39%), nausea (33%), and headache (26%).
USE IN SPECIFIC POPULATIONS
PregnancyThere are no data from the use of
setmelanotide in pregnant women. Animal studies do not indicate
direct harmful effects with respect to reproductive toxicity.
However, administration of setmelanotide to pregnant rabbits
resulted in decreased maternal food consumption leading to
embryo-fetal effects. As a precautionary measure, setmelanotide
should not be started during pregnancy or while attempting to get
pregnant as weight loss during pregnancy may result in fetal harm.
If a patient who is taking setmelanotide has reached a stable
weight and becomes pregnant, consideration should be given to
maintaining setmelanotide treatment as there was no proof of
teratogenicity in the nonclinical data. If a patient who is taking
setmelanotide and still losing weight gets pregnant, setmelanotide
should either be discontinued, or the dose reduced while monitoring
for the recommended weight gain during pregnancy. The treating
physician should carefully monitor weight during pregnancy in a
patient taking setmelanotide.
Breast-feedingIt is unknown whether
setmelanotide is excreted in human milk. A nonclinical study showed
that setmelanotide is excreted in the milk of nursing rats. No
quantifiable setmelanotide concentrations were detected in plasma
from nursing pups. A risk to the newborn/infant cannot be excluded.
A decision must be made whether to discontinue breastfeeding or to
discontinue/abstain from setmelanotide therapy taking into account
the benefit of breastfeeding for the child and the benefit of
therapy for the mother.
FertilityNo human data on the effect of
setmelanotide on fertility are available. Animal studies did not
indicate harmful effects with respect to fertility.
To report SUSPECTED ADVERSE REACTIONS, contact Rhythm
Pharmaceuticals at +1 (833) 789-6337. See Summary of
Product Characteristics’ APPENDIX V for a list of
European national reporting systems to communicate adverse
reactions.
Please see the full Prescribing Information for
additional Important Safety Information.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the safety, efficacy, and regulatory and clinical design
or progress, potential regulatory submissions, approvals and timing
thereof of setmelanotide and LB54640, including our Phase 3 trial
of setmelanotide for patients with hypothalamic obesity in Japan,
the United States or in Europe, the potential benefits of
setmelanotide for patients with hypothalamic obesity, our
expectations surrounding potential regulatory submissions,
approvals and timing thereof, including the IND application for
RM-718, the Company’s business strategy and plans, including
regarding commercialization of setmelanotide, expectations
surrounding sales and reimbursement of IMCIVREE, our anticipated
financial performance and financial position, including estimated
Non-GAAP Operating Expenses for the year ending December 31, 2024,
the sufficiency of our cash, cash equivalents and short-term
investments to fund our operations. Statements using words such as
“expect”, “anticipate”, “believe”, “may”, “will”, “aim” and similar
terms are also forward-looking statements. Such statements are
subject to numerous risks and uncertainties, including, but not
limited to, our ability to enroll patients in clinical trials, the
design and outcome of clinical trials, the ability to achieve
necessary regulatory approvals, risks associated with data analysis
and reporting, failure to identify and develop additional product
candidates, unfavorable pricing regulations, third-party
reimbursement practices or healthcare reform initiatives, risks
associated with the laws and regulations governing our
international operations and the costs of any related compliance
programs, the impact of competition, risks relating to product
liability lawsuits, inability to maintain collaborations, or the
failure of these collaborations, our reliance on third parties,
risks relating to intellectual property, our ability to hire and
retain necessary personnel, general economic conditions, risks
related to internal control over financial reporting, and the other
important factors discussed under the caption “Risk Factors” in our
Quarterly Report on Form 10-Q for the quarter ended September 30,
2023 and our other filings with the Securities and Exchange
Commission. Except as required by law, we undertake no obligations
to make any revisions to the forward-looking statements contained
in this press release or to update them to reflect events or
circumstances occurring after the date of this press release,
whether as a result of new information, future developments or
otherwise.
Non-GAAP Financial
MeasuresThis press release includes Non-GAAP Operating
Expenses, a supplemental measure of our performance that is not
required by, or presented in accordance with, U.S. GAAP and should
not be considered as an alternative to operating expenses or any
other performance measure derived in accordance with GAAP.
We define Non-GAAP Operating Expenses
as GAAP operating expenses excluding stock-based compensation and
fixed consideration related to in-licensing.
We caution investors that amounts
presented in accordance with our definition of Non-GAAP Operating
Expenses may not be comparable to similar measures disclosed by our
competitors because not all companies and analysts calculate this
non-GAAP financial measure in the same manner. We present this
non-GAAP financial measure because we consider it to be an
important supplemental measure of our performance and believe it is
frequently used by securities analysts, investors, and other
interested parties in the evaluation of companies in our industry.
Management believes that investors’ understanding of our
performance is enhanced by including this non-GAAP financial
measure as a reasonable basis for comparing our ongoing results of
operations.
Management uses this non-GAAP
financial measure for planning purposes, including the preparation
of our internal annual operating budget and financial projections;
to evaluate the performance and effectiveness of our operational
strategies; and to evaluate our capacity to expand our business.
This non-GAAP financial measure has limitations as an analytical
tool, and should not be considered in isolation, or as an
alternative to, or a substitute for operating expenses or other
financial statement data presented in accordance with GAAP in our
consolidated financial statements.
Rhythm has not provided a quantitative
reconciliation of forecasted Non-GAAP Operating Expenses to
forecasted GAAP operating expenses because the Company is unable,
without making unreasonable efforts, to calculate the reconciling
items, stock-based compensation expenses and fixed consideration
related to in-licensing, with confidence. These items, which could
materially affect the computation of forward-looking GAAP operating
expenses, are inherently uncertain and depends on various factors,
some of which are outside of Rhythm's control.
Corporate
Contact:David ConnollyExecutive Director, Investor
Relations and Corporate CommunicationsRhythm Pharmaceuticals,
Inc.857-264-4280dconnolly@rhythmtx.com
Media Contact:Adam
DaleyBerry & Company Public
Relations212-253-8881adaley@berrypr.com
Rhythm Pharmaceuticals, Inc.Condensed
Consolidated Statements of Operations(in
thousands, except share and per share
data)(Unaudited) |
|
Three months ended December 31, |
Twelve months ended December 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
|
|
|
Revenues: |
|
|
|
|
Product revenue, net |
$ |
24,234 |
|
|
$ |
8,790 |
|
|
$ |
77,428 |
|
|
$ |
16,884 |
|
License revenue |
|
-- |
|
|
|
- |
|
|
|
- |
|
|
|
6,754 |
|
|
|
|
|
|
Costs and expenses: |
|
|
|
|
Cost of sales |
|
3,233 |
|
|
|
1,028 |
|
|
|
9,302 |
|
|
|
2,133 |
|
Research and development |
|
29,892 |
|
|
|
23,548 |
|
|
|
134,951 |
|
|
|
108,630 |
|
Selling, general, and administrative |
|
32,374 |
|
|
|
26,318 |
|
|
|
117,532 |
|
|
|
92,032 |
|
Total Costs and expenses |
|
65,499 |
|
|
|
50,894 |
|
|
|
261,785 |
|
|
|
202,795 |
|
Loss from operations |
|
(41,265 |
) |
|
|
(42,104 |
) |
|
|
(184,357 |
) |
|
|
(179,157 |
) |
Other income (expense): |
|
|
|
|
Other income (expense), net |
|
39 |
|
|
|
(420 |
) |
|
|
190 |
|
|
|
(790 |
) |
Interest expense |
|
(4,018 |
) |
|
|
(3,010 |
) |
|
|
(13,892 |
) |
|
|
(5,201 |
) |
Interest income |
|
3,819 |
|
|
|
3,040 |
|
|
|
13,945 |
|
|
|
4,029 |
|
Total other income (expense): |
|
(160 |
) |
|
|
(390 |
) |
|
|
243 |
|
|
|
(1,962 |
) |
Net loss before taxes |
|
(41,425 |
) |
|
|
(42,494 |
) |
|
|
(184,114 |
) |
|
|
(181,119 |
) |
Provision for taxes |
|
196 |
|
|
|
|
564 |
|
|
|
-- |
|
Net loss |
$ |
(41,621 |
) |
|
$ |
(42,494 |
) |
|
$ |
(184,678 |
) |
|
$ |
(181,119 |
) |
Net loss per share, basic and
diluted |
$ |
(0.70 |
) |
|
$ |
(0.75 |
) |
|
$ |
(3.20 |
) |
|
$ |
(3.47 |
) |
Weighted-average common shares
outstanding, basic and diluted |
|
59,211,199 |
|
|
|
56,299,525 |
|
|
|
57,673,128 |
|
|
|
52,120,701 |
|
RHYTHM PHARMACEUTICALS,
INC.CONDENSED CONSOLIDATED BALANCE
SHEETS(in thousands, except share and per share
data)Unaudited |
|
|
December 31, |
|
December 31, |
|
|
2023 |
|
|
2022 |
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
60,081 |
|
|
$ |
127,677 |
|
Short-term investments |
|
|
215,765 |
|
|
|
205,611 |
|
Accounts receivable, net |
|
|
14,867 |
|
|
|
6,224 |
|
Inventory |
|
|
8,624 |
|
|
|
2,917 |
|
Prepaid expenses and other
current assets |
|
|
8,931 |
|
|
|
11,807 |
|
Total current assets |
|
|
308,268 |
|
|
|
354,236 |
|
Property and equipment,
net |
|
|
1,341 |
|
|
|
2,197 |
|
Right-of-use asset |
|
|
781 |
|
|
|
1,182 |
|
Intangible assets, net |
|
|
7,028 |
|
|
|
7,883 |
|
Restricted cash |
|
|
328 |
|
|
|
328 |
|
Other long-term assets |
|
|
14,999 |
|
|
|
16,655 |
|
Total assets |
|
$ |
332,745 |
|
|
$ |
382,481 |
|
Liabilities and
stockholders’ equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
4,885 |
|
|
$ |
4,797 |
|
Accrued expenses and other
current liabilities |
|
|
48,262 |
|
|
|
32,894 |
|
Deferred revenue |
|
|
1,286 |
|
|
|
1,434 |
|
Lease liability |
|
|
770 |
|
|
|
684 |
|
Total current liabilities |
|
|
55,203 |
|
|
|
39,809 |
|
Long-term liabilities: |
|
|
|
|
|
|
Other long-term
liabilities |
|
|
106,143 |
|
|
|
75,810 |
|
Lease liability |
|
|
490 |
|
|
|
1,260 |
|
Derivative liability |
|
|
1,150 |
|
|
|
1,340 |
|
Total liabilities |
|
|
162,986 |
|
|
|
118,219 |
|
Stockholders’ equity: |
|
|
|
|
|
|
Preferred Stock, $0.001 par
value: 10,000,000 shares authorized; no shares issued and
outstanding at December 31, 2023 and December 31, 2022 |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par
value: 120,000,000 shares authorized; 59,426,559 and 56,612,429
shares issued and outstanding at December 31, 2023 and December 31,
2022, respectively |
|
|
59 |
|
|
|
56 |
|
Additional paid-in
capital |
|
|
1,064,302 |
|
|
|
974,356 |
|
Accumulated other
comprehensive loss |
|
|
134 |
|
|
|
(92 |
) |
Accumulated deficit |
|
|
(894,736 |
) |
|
|
(710,058 |
) |
Total stockholders’
equity |
|
|
169,759 |
|
|
|
264,262 |
|
Total liabilities and
stockholders’ equity |
|
$ |
332,745 |
|
|
$ |
382,481 |
|
Rhythm Pharmaceuticals (NASDAQ:RYTM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024